CalciMedica (CALC)

Executive Summary

CalciMedica is a clinical-stage biopharmaceutical company pioneering CRAC channel inhibition therapies for acute inflammatory and immunologic diseases. Its lead candidate, Auxora (zegocractin), is an intravenous small-molecule CRAC channel inhibitor being developed for acute kidney injury (AKI) and acute pancreatitis (AP), conditions with high unmet need. The company has completed Phase 1/2 trials and is advancing toward pivotal studies. With a novel mechanism targeting calcium signaling, CalciMedica aims to address the inflammatory cascade in these acute settings, potentially offering a first-in-class treatment option. The company is publicly traded under ticker CALC and is headquartered in La Jolla, California. Recent developments include positive Phase 2 data in AKI and AP, showing proof of concept. CalciMedica is preparing for end-of-Phase 2 meetings with the FDA and expects to initiate a pivotal Phase 3 trial in the near future. The company's strong intellectual property position and niche focus on CRAC channels differentiate it in the inflammation space. However, execution risk remains as it transitions to late-stage development. With a lean pipeline and a targeted approach, CalciMedica represents a high-risk, high-reward opportunity in acute care settings.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 AKI Topline Results70% success
• Q4 2026FDA End-of-Phase 2 Meeting for AKI80% success
• Q1 2027Phase 3 AP Trial Initiation60% success